Elidel crème 1% reçoit l'autorisation de mise sur le marché en Suisse
| Source: Novartis Pharma AG
Recommended Reading
-
Cosentyx® (secukinumab) doubled sustained remission rates and demonstrated steroid-sparing effects vs placebo in Phase III trial¹Approval marks 11th US indication for Cosentyx, building on its...
Read More -
If approved, Cosentyx® (secukinumab) will become the only IL-17A inhibitor for adolescents with moderate to severe HS in Europe1,2HS affects as many as one in 100 people worldwide,3 with more than...
Read More